Consolidated Statements of Operations (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Revenue
Licensing revenue	$ 104,000	$ 22,000	$ 81,000
Total revenue	104,000	22,000	81,000
Operating expenses
Research and development	1,011,000	641,000	6,469,000
General and administrative	1,627,000	714,000	5,996,000
Total operating expenses	2,638,000	1,355,000	12,465,000
Loss from operations	(2,534,000)	(1,333,000)	(12,384,000)
Other income (expenses)
Gain (loss) on derivative liabilities	(8,773,000)	87,000	(49,330,000)
Amortization of note discount	0	(303,000)	(2,636,000)
Interest expense, net	0	(96,000)	(233,000)
Total other expense	(8,773,000)	(312,000)	(52,199,000)
Net loss	(11,307,000)	(1,645,000)	(64,583,000)
Accretion of Series B redeemable convertible preferred stock	(314,000)	0	(618,000)
Net loss attributable to common stockholders	$ (11,621,000)	$ (1,645,000)	$ (65,201,000)
Per share information:
Net loss per share - basic & diluted (in dollars per share)	$ (0.06)	$ (0.03)	$ (0.64)
Weighted average number of shares of common stock outstanding - basic & diluted (in shares)	182,535,562	66,908,810	101,201,753